CMS is planning to scrap its contentious breakthrough payment rule after concluding it is not in the best interest of Medicare beneficiaries.
The Medicare Coverage of Innovative Technology (MCIT) pathway would have allowed medtech companies to secure near-automatic coverage for a period of four years with an FDA breakthrough device designation.
